Syndax Pharmaceuticals Inc [SNDX] stock prices are up 7.47% to $14.10 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have gain 7.63% over the last week, with a monthly amount drifted -4.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $37. Previously, Jefferies started tracking the stock with Buy rating on June 28, 2024, and set its price target to $37. On January 31, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $23 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $45 on December 22, 2023. BofA Securities initiated its recommendation with a Buy and recommended $29 as its price target on October 25, 2023. Goldman started tracking with a Buy rating for this stock on October 11, 2023, and assigned it a price target of $30. In a note dated July 27, 2023, Scotiabank initiated an Sector Outperform rating.
The stock price of Syndax Pharmaceuticals Inc [SNDX] has been fluctuating between $12.06 and $25.07 over the past year. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $14.10 at the most recent close of the market. An investor can expect a potential return of 95.04% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at -0.87% with Operating Profit Margin at -14.34%, Pretax Profit Margin comes in at -13.46%, and Net Profit Margin reading is -13.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.81 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.37 points at the first support level, and at 12.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.51, and for the 2nd resistance point, it is at 14.92.
Ratios To Look Out For
It’s worth pointing out that Syndax Pharmaceuticals Inc [NASDAQ:SNDX]’s Current Ratio is 5.82. As well, the Quick Ratio is 5.82, while the Cash Ratio is 1.49. Considering the valuation of this stock, the price to sales ratio is 51.22, the price to book ratio is 4.19.
Transactions by insiders
Recent insider trading involved Metzger Michael A, Chief Executive Officer, that happened on Mar 04 ’25 when 7814.0 shares were sold. Officer, MICHAEL METZGER completed a deal on Mar 04 ’25 to buy 13888.0 shares. Meanwhile, Chief Financial Officer Goldan Keith A. sold 3777.0 shares on Feb 10 ’25.
